Observation On The Germination Of The Seeds Of Crinum Macowani,Baker

Arid and semi-arid areas occupy an increasing fraction of the Earth's surface. Legume floras exist for most of these areas, but there is little information as to whether the plants nodulate and fix nitrogen (N) in their native habitats, although many have been used over millennia for food, forage and medicinal and other uses.

This review shows that, in those arid and semi-arid areas where data are available, the ability of legumes to nodulate is a significant attribute. It examines some host genera present and, where known, the bacteria that induce nodulation in them.

With some exceptions all legumes from well-studied arid areas have the potential to nodulate. Semi-arid areas vary between continents in terms of legume genera present, the probable extent of N fixation and in the endosymbionts (rhizobia) that induce nodulation in them.

With climate change and an increasing world population, there is an urgent need to develop the diverse range of nodulated legumes native to dry environments. With modern methods this goal is readily achievable.     

Comparison Of The Efficacy,Adverse Effects,And Cost Of Zoledronic Acid And Denosumab In The Treatment Of Osteoporosis

ObjectiveInjectable osteoporosis drugs are increasing in popularity due to their efficacy and convenient administration. In this retrospective comparison of the two available treatments, denosumab (Prolia®) and zoledronic acid (ZA, Reclast®), we aimed to determine and compare the efficacy and tolerability of denosumab and ZA.MethodsThe charts of patients who received denosumab and ZA at Loyola Hospital were reviewed, and adverse events were noted. Of primary interest were myalgias, flu-like symptoms, back pain, and fractures. A questionnaire regarding the efficacy, tolerability, and treatment cost supplemented this chart review in a subset of study participants. Bone mineral density (BMD) changes, bone turnover markers, and questionnaire results were also compared.ResultsThe study cohort consisted of 107 patients (51 denosumab, 56 ZA). The denosumab group had a greater mean increase in spine BMD at 1 year (0.060 g/cm²) than the ZA group (0.021 g/cm²; P = .04). The change in femur and spine BMD at 1 year were not significantly different between the 2 groups. The ZA group had a significantly greater incidence of mild flu-like symptoms (29% ZA group vs. 0% denosumab group; P = .04).ConclusionThe denosumab group had a higher mean increase in spine BMD, and the ZA group had a higher incidence of flu-like symptoms, but the study groups were statistically similar in terms of patient satisfaction. As denosumab is still a relatively new therapy, there were a limited number of patients with posttreatment data available for comparison. As more posttherapy data become available, it can be further investigated. (Endocr Pract. 2015;21:275-279)